These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 38384294)
1. Soluble guanylate cyclase stimulators and activators: new horizons in the treatment of priapism associated with sickle cell disease. Pereira DA; Silveira THR; Calmasini FB; Silva FH Front Pharmacol; 2024; 15():1357176. PubMed ID: 38384294 [TBL] [Abstract][Full Text] [Related]
2. Nitric Oxide Resistance in Priapism Associated with Sickle Cell Disease: Mechanisms, Therapeutic Challenges, and Future Directions. Pereira DA; Calmasini FB; Costa FF; Burnett AL; Silva FH J Pharmacol Exp Ther; 2024 Jul; 390(2):203-212. PubMed ID: 38262744 [TBL] [Abstract][Full Text] [Related]
3. Targeting heme in sickle cell disease: new perspectives on priapism treatment. Silveira THR; Calmasini FB; de Oliveira MG; Costa FF; Silva FH Front Physiol; 2024; 15():1435220. PubMed ID: 39086934 [TBL] [Abstract][Full Text] [Related]
5. Modulation of soluble guanylate cyclase for the treatment of erectile dysfunction. Lasker GF; Pankey EA; Kadowitz PJ Physiology (Bethesda); 2013 Jul; 28(4):262-9. PubMed ID: 23817801 [TBL] [Abstract][Full Text] [Related]
6. Intravascular hemolysis leads to exaggerated corpus cavernosum relaxation: Implication for priapism in sickle cell disease. Iacopucci APM; da Silva Pereira P; Pereira DA; Calmasini FB; Pittalà V; Reis LO; Burnett AL; Costa FF; Silva FH FASEB J; 2022 Oct; 36(10):e22535. PubMed ID: 36070139 [TBL] [Abstract][Full Text] [Related]
7. Mechanisms underlying priapism in sickle cell disease: targeting and key innovations on the preclinical landscape. Musicki B; Burnett AL Expert Opin Ther Targets; 2020 May; 24(5):439-450. PubMed ID: 32191546 [No Abstract] [Full Text] [Related]
8. Haptoglobin treatment contributes to regulating nitric oxide signal and reduces oxidative stress in the penis: A preventive treatment for priapism in sickle cell disease. Pereira PDS; Pereira DA; Calmasini FB; Reis LO; Brinkman N; Burnett AL; Costa FF; Silva FH Front Physiol; 2022; 13():961534. PubMed ID: 36176769 [No Abstract] [Full Text] [Related]
9. Hydroxyurea does not reverse functional alterations of the nitric oxide-cGMP pathway associated with priapism phenotype in corpus cavernosum from sickle cell mouse. Pereira DA; Pereira DA; da Silva Pereira P; Silveira THR; Calmasini FB; Reis LO; Costa FF; Silva FH PLoS One; 2023; 18(10):e0292706. PubMed ID: 37812620 [TBL] [Abstract][Full Text] [Related]
11. Increased cavernosal relaxations in sickle cell mice priapism are associated with alterations in the NO-cGMP signaling pathway. Claudino MA; Franco-Penteado CF; Corat MA; Gimenes AP; Passos LA; Antunes E; Costa FF J Sex Med; 2009 Aug; 6(8):2187-96. PubMed ID: 19493282 [TBL] [Abstract][Full Text] [Related]
12. Beneficial Effect of the Nitric Oxide Donor Compound 3-(1,3-Dioxoisoindolin-2-yl)Benzyl Nitrate on Dysregulated Phosphodiesterase 5, NADPH Oxidase, and Nitrosative Stress in the Sickle Cell Mouse Penis: Implication for Priapism Treatment. Silva FH; Karakus S; Musicki B; Matsui H; Bivalacqua TJ; Dos Santos JL; Costa FF; Burnett AL J Pharmacol Exp Ther; 2016 Nov; 359(2):230-237. PubMed ID: 27540002 [TBL] [Abstract][Full Text] [Related]
13. Priapism and sickle-cell anemia: diagnosis and nonsurgical therapy. Broderick GA J Sex Med; 2012 Jan; 9(1):88-103. PubMed ID: 21699659 [TBL] [Abstract][Full Text] [Related]
14. Heme-induced corpus cavernosum relaxation and its implications for priapism in sickle cell disease: a mechanistic insight. Pereira DA; Pereira DA; Silveira THR; Calmasini FB; Burnett AL; Costa FF; Silva FH Andrology; 2024 Jan; ():. PubMed ID: 38231174 [TBL] [Abstract][Full Text] [Related]
15. Exploring the potential of NO-independent stimulators and activators of soluble guanylate cyclase for the medical treatment of erectile dysfunction. Gur S; Kadowitz PJ; Hellstrom WJ Curr Pharm Des; 2010 May; 16(14):1619-33. PubMed ID: 20201788 [TBL] [Abstract][Full Text] [Related]
16. The Role of sGC Stimulators and Activators in Heart Failure With Reduced Ejection Fraction. Cordwin DJ; Berei TJ; Pogue KT J Cardiovasc Pharmacol Ther; 2021 Nov; 26(6):593-600. PubMed ID: 34487435 [TBL] [Abstract][Full Text] [Related]
17. Activators of soluble guanylate cyclase for the treatment of male erectile dysfunction. Brioni JD; Nakane M; Hsieh GC; Moreland RB; Kolasa T; Sullivan JP Int J Impot Res; 2002 Feb; 14(1):8-14. PubMed ID: 11896472 [TBL] [Abstract][Full Text] [Related]
18. Nitric Oxide-Independent Soluble Guanylate Cyclase Activation Improves Vascular Function and Cardiac Remodeling in Sickle Cell Disease. Potoka KP; Wood KC; Baust JJ; Bueno M; Hahn SA; Vanderpool RR; Bachman T; Mallampalli GM; Osei-Hwedieh DO; Schrott V; Sun B; Bullock GC; Becker-Pelster EM; Wittwer M; Stampfuss J; Mathar I; Stasch JP; Truebel H; Sandner P; Mora AL; Straub AC; Gladwin MT Am J Respir Cell Mol Biol; 2018 May; 58(5):636-647. PubMed ID: 29268036 [TBL] [Abstract][Full Text] [Related]
19. Soluble Guanylate Cyclase Stimulators and Activators: Where are We and Where to Go? Xiao S; Li Q; Hu L; Yu Z; Yang J; Chang Q; Chen Z; Hu G Mini Rev Med Chem; 2019; 19(18):1544-1557. PubMed ID: 31362687 [TBL] [Abstract][Full Text] [Related]
20. Prolonged therapy with the soluble guanylyl cyclase activator BAY 60-2770 restores the erectile function in obese mice. Silva FH; Leiria LO; Alexandre EC; Davel AP; Mónica FZ; De Nucci G; Antunes E J Sex Med; 2014 Nov; 11(11):2661-70. PubMed ID: 25196910 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]